RECURSION PHARMACEUTICALS, INC. Investment Income, Nonoperating
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Investment Income, Nonoperating of $5.31 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeNonoperating · last filed 2026-08-05
- RECURSION PHARMACEUTICALS, INC. investment income, nonoperating for the quarter ending 2026-06-30 was $5.31M, a 2.52% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. investment income, nonoperating for the quarter ending 2026-03-31 was $5.96M, a 7.29% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. investment income, nonoperating for the quarter ending 2025-12-31 was $6.25M, a 35.22% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. investment income, nonoperating for the quarter ending 2025-09-30 was $5.54M, a 44.80% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. investment income, nonoperating for fiscal 2025 was $22.79M, a 44.61% increase from fiscal 2024.
- RECURSION PHARMACEUTICALS, INC. investment income, nonoperating for fiscal 2024 was $15.76M, a 17.57% decline from fiscal 2023.
- RECURSION PHARMACEUTICALS, INC. investment income, nonoperating for fiscal 2023 was $19.12M, a 205.66% increase from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. investment income, nonoperating for fiscal 2022 was $6.25M, a 8467.12% increase from fiscal 2021.
| Period end | Investment Income, Nonoperating 3 month | Investment Income, Nonoperating 6 month | Investment Income, Nonoperating 9 month | Investment Income, Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.31M 10-Q · filed 2026-08-05 | $11.27M 10-Q · filed 2026-08-05 | $17.52M derived: sum of 3 quarters · filed 2026-08-05 | $23.06M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $5.96M 10-Q · filed 2026-05-06 | $12.21M derived: sum of 2 quarters · filed 2026-05-06 | $17.75M derived: sum of 3 quarters · filed 2026-05-06 | $23.19M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $6.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $11.79M derived: sum of 2 quarters · filed 2026-02-25 | $17.23M derived: sum of 3 quarters · filed 2026-08-05 | $22.79M 10-K · filed 2026-02-25 |
| 2025-09-30 | $5.54M 10-Q · filed 2025-11-05 | $10.98M derived: sum of 2 quarters · filed 2026-08-05 | $16.54M 10-Q · filed 2025-11-05 | $21.16M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $5.44M 10-Q · filed 2026-08-05 | $11.00M 10-Q · filed 2026-08-05 | $15.62M derived: sum of 3 quarters · filed 2026-08-05 | $19.45M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $5.56M 10-Q · filed 2026-05-06 | $10.18M derived: sum of 2 quarters · filed 2026-05-06 | $14.00M derived: sum of 3 quarters · filed 2026-05-06 | $17.27M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $4.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $8.45M derived: sum of 2 quarters · filed 2026-02-25 | $11.71M derived: sum of 3 quarters · filed 2026-02-25 | $15.76M 10-K · filed 2026-02-25 |
| 2024-09-30 | $3.83M 10-Q · filed 2025-11-05 | $7.09M derived: sum of 2 quarters · filed 2025-11-05 | $11.14M 10-Q · filed 2025-11-05 | $15.66M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $3.27M 10-Q · filed 2025-08-05 | $7.31M 10-Q · filed 2025-08-05 | $11.84M derived: sum of 3 quarters · filed 2026-02-25 | $16.81M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $4.05M 10-Q · filed 2025-05-05 | $8.57M derived: sum of 2 quarters · filed 2026-02-25 | $13.55M derived: sum of 3 quarters · filed 2026-02-25 | $18.50M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $4.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $9.50M derived: sum of 2 quarters · filed 2026-02-25 | $14.46M derived: sum of 3 quarters · filed 2026-02-25 | $19.12M 10-K · filed 2026-02-25 |
| 2023-09-30 | $4.98M 10-Q · filed 2024-11-06 | $9.93M derived: sum of 2 quarters · filed 2024-11-06 | $14.59M 10-Q · filed 2024-11-06 | $18.28M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $4.96M 10-Q · filed 2024-08-08 | $9.62M 10-Q · filed 2024-08-08 | $13.30M derived: sum of 3 quarters · filed 2025-02-28 | $15.13M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $4.66M 10-Q · filed 2024-05-09 | $8.34M derived: sum of 2 quarters · filed 2025-02-28 | $10.18M derived: sum of 3 quarters · filed 2025-02-28 | $10.83M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $3.68M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $5.51M derived: sum of 2 quarters · filed 2025-02-28 | $6.17M derived: sum of 3 quarters · filed 2025-02-28 | $6.25M 10-K · filed 2025-02-28 |
| 2022-09-30 | $1.83M 10-Q · filed 2023-11-09 | $2.48M derived: sum of 2 quarters · filed 2023-11-09 | $2.57M 10-Q · filed 2023-11-09 | $2.55M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $652.00K 10-Q · filed 2023-08-08 | $739.00K 10-Q · filed 2023-08-08 | $718.00K derived: sum of 3 quarters · filed 2024-02-29 | $768.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $87.00K 10-Q · filed 2023-05-08 | $66.00K derived: sum of 2 quarters · filed 2024-02-29 | $116.00K derived: sum of 3 quarters · filed 2024-02-29 | $145.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | -$21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $29.00K derived: sum of 2 quarters · filed 2024-02-29 | $58.00K derived: sum of 3 quarters · filed 2024-02-29 | $73.00K 10-K · filed 2024-02-29 |
| 2021-09-30 | $50.00K 10-Q · filed 2022-11-08 | $79.00K derived: sum of 2 quarters · filed 2022-11-08 | $94.00K 10-Q · filed 2022-11-08 | $141.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $29.00K 10-Q · filed 2022-08-09 | $45.00K 10-Q · filed 2022-08-09 | $91.00K derived: sum of 3 quarters · filed 2023-02-27 | $137.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $16.00K 10-Q · filed 2022-05-10 | $62.00K derived: sum of 2 quarters · filed 2023-02-27 | $108.00K derived: sum of 3 quarters · filed 2023-02-27 | $132.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $46.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $92.00K derived: sum of 2 quarters · filed 2023-02-27 | $116.00K derived: sum of 3 quarters · filed 2023-02-27 | $336.00K 10-K · filed 2023-02-27 |
| 2020-09-30 | $46.00K 10-Q · filed 2021-11-10 | $70.00K derived: sum of 2 quarters · filed 2021-11-10 | $290.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $24.00K 10-Q · filed 2021-08-13 | $244.00K 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $220.00K 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | $1.74M 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |